To view this content, you need to sign in.
You should only be asked to sign in once. Not the case? Click here
Register now to access this content and more for free.
Ampersand sells Nexcelom Bioscience for $260m
Ampersand Capital Partners has sold Nexcelom Bioscience to PerkinElmer for $260 million.
